Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,591 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial.
Gough SC, Bhargava A, Jain R, Mersebach H, Rasmussen S, Bergenstal RM. Gough SC, et al. Among authors: rasmussen s. Diabetes Care. 2013 Sep;36(9):2536-42. doi: 10.2337/dc12-2329. Epub 2013 May 28. Diabetes Care. 2013. PMID: 23715753 Free PMC article. Clinical Trial.
Insulin degludec is not associated with a delayed or diminished response to hypoglycaemia compared with insulin glargine in type 1 diabetes: a double-blind randomised crossover study.
Koehler G, Heller S, Korsatko S, Roepstorff C, Rasmussen S, Haahr H, Pieber TR. Koehler G, et al. Among authors: rasmussen s. Diabetologia. 2014 Jan;57(1):40-9. doi: 10.1007/s00125-013-3056-0. Epub 2013 Sep 22. Diabetologia. 2014. PMID: 24057153 Free PMC article. Clinical Trial.
No Evidence of Increase in Calcitonin Concentrations or Development of C-Cell Malignancy in Response to Liraglutide for Up to 5 Years in the LEADER Trial.
Hegedüs L, Sherman SI, Tuttle RM, von Scholten BJ, Rasmussen S, Karsbøl JD, Daniels GH; LEADER Publication Committee on behalf of the LEADER Trial Investigators. Hegedüs L, et al. Among authors: rasmussen s. Diabetes Care. 2018 Mar;41(3):620-622. doi: 10.2337/dc17-1956. Epub 2017 Dec 26. Diabetes Care. 2018. PMID: 29279300 Clinical Trial.
Hypoglycemia, Cardiovascular Outcomes, and Death: The LEADER Experience.
Zinman B, Marso SP, Christiansen E, Calanna S, Rasmussen S, Buse JB; LEADER Publication Committee on behalf of the LEADER Trial Investigators. Zinman B, et al. Among authors: rasmussen s. Diabetes Care. 2018 Aug;41(8):1783-1791. doi: 10.2337/dc17-2677. Epub 2018 Jun 14. Diabetes Care. 2018. PMID: 29903847 Clinical Trial.
Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: A 30-week, double-blind, phase 3a, randomized trial.
Ji L, Dong X, Li Y, Li Y, Lim S, Liu M, Ning Z, Rasmussen S, Skjøth TV, Yuan G, Eliaschewitz FG. Ji L, et al. Among authors: rasmussen s. Diabetes Obes Metab. 2021 Feb;23(2):404-414. doi: 10.1111/dom.14232. Epub 2021 Jan 3. Diabetes Obes Metab. 2021. PMID: 33074557 Free PMC article. Clinical Trial.
Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial.
Persson F, Bain SC, Mosenzon O, Heerspink HJL, Mann JFE, Pratley R, Raz I, Idorn T, Rasmussen S, von Scholten BJ, Rossing P; LEADER Trial Investigators. Persson F, et al. Among authors: rasmussen s. Diabetes Care. 2021 Apr;44(4):1020-1026. doi: 10.2337/dc20-1622. Epub 2021 Jan 27. Diabetes Care. 2021. PMID: 33504496 Free PMC article. Clinical Trial.
Response to Comment on Nauck et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care 2019;42:1912-1920.
Nauck MA, Kreiner E, Rasmussen S, Saevereid HA, Buse JB; LEADER Trial Investigators. Nauck MA, et al. Among authors: rasmussen s. Diabetes Care. 2020 Feb;43(2):e30-e31. doi: 10.2337/dci19-0067. Diabetes Care. 2020. PMID: 31959650 Free PMC article. No abstract available.
Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from the LEADER randomized trial.
Mosenzon O, Bain SC, Heerspink HJL, Idorn T, Mann JFE, Persson F, Pratley RE, Rasmussen S, Rossing P, von Scholten BJ, Raz I; LEADER Trial Investigators. Mosenzon O, et al. Among authors: rasmussen s. Diabetes Obes Metab. 2020 Nov;22(11):2077-2088. doi: 10.1111/dom.14126. Epub 2020 Aug 7. Diabetes Obes Metab. 2020. PMID: 32618386 Free PMC article. Clinical Trial.
2,591 results